Literature DB >> 19465897

Diabetes: Which risk engines should be used to assess patients with diabetes?

Kausik K Ray, Naveed Sattar.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19465897     DOI: 10.1038/nrendo.2009.100

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.

Authors:  John B Buse; Henry N Ginsberg; George L Bakris; Nathaniel G Clark; Fernando Costa; Robert Eckel; Vivian Fonseca; Hertzel C Gerstein; Scott Grundy; Richard W Nesto; Michael P Pignone; Jorge Plutzky; Daniel Porte; Rita Redberg; Kimberly F Stitzel; Neil J Stone
Journal:  Circulation       Date:  2006-12-27       Impact factor: 29.690

2.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

3.  Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies.

Authors:  Josie M M Evans; Jixian Wang; Andrew D Morris
Journal:  BMJ       Date:  2002-04-20

4.  Preventing microalbuminuria in type 2 diabetes.

Authors:  Piero Ruggenenti; Anna Fassi; Anelja Parvanova Ilieva; Simona Bruno; Ilian Petrov Iliev; Varusca Brusegan; Nadia Rubis; Giulia Gherardi; Federica Arnoldi; Maria Ganeva; Bogdan Ene-Iordache; Flavio Gaspari; Annalisa Perna; Antonio Bossi; Roberto Trevisan; Alessandro R Dodesini; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

Review 5.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

6.  Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes.

Authors:  H C Price; R L Coleman; R J Stevens; R R Holman
Journal:  Diabetologia       Date:  2008-12-02       Impact factor: 10.122

7.  The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.

Authors:  J Danesh; S Erqou; M Walker; S G Thompson; R Tipping; C Ford; S Pressel; G Walldius; I Jungner; A R Folsom; L E Chambless; M Knuiman; P H Whincup; S G Wannamethee; R W Morris; J Willeit; S Kiechl; P Santer; A Mayr; N Wald; S Ebrahim; D A Lawlor; J W G Yarnell; J Gallacher; E Casiglia; V Tikhonoff; P J Nietert; S E Sutherland; D L Bachman; J E Keil; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; B G Nordestgaard; R Frikke-Schmidt; S Giampaoli; L Palmieri; S Panico; D Vanuzzo; L Pilotto; L Simons; J McCallum; Y Friedlander; F G R Fowkes; A J Lee; F B Smith; J Taylor; J Guralnik; C Phillips; R Wallace; D Blazer; K T Khaw; J H Jansson; C Donfrancesco; V Salomaa; K Harald; P Jousilahti; E Vartiainen; M Woodward; R B D'Agostino; P A Wolf; R S Vasan; M J Pencina; E M Bladbjerg; T Jorgensen; L Moller; J Jespersen; R Dankner; A Chetrit; F Lubin; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; C Bjorkelund; P Cremer; D Nagel; R Tilvis; T Strandberg; B Rodriguez; L M Bouter; R J Heine; J M Dekker; G Nijpels; C D A Stehouwer; E Rimm; J Pai; S Sato; H Iso; A Kitamura; H Noda; U Goldbourt; V Salomaa; J T Salonen; K Nyyssönen; T-P Tuomainen; D Deeg; J L Poppelaars; T Meade; J Cooper; B Hedblad; G Berglund; G Engstrom; A Döring; W Koenig; C Meisinger; W Mraz; L Kuller; R Selmer; A Tverdal; W Nystad; R Gillum; M Mussolino; S Hankinson; J Manson; B De Stavola; C Knottenbelt; J A Cooper; K A Bauer; R D Rosenberg; S Sato; Y Naito; I Holme; H Nakagawa; H Miura; P Ducimetiere; X Jouven; C Crespo; M Garcia-Palmieri; P Amouyel; D Arveiler; A Evans; J Ferrieres; H Schulte; G Assmann; J Shepherd; C Packard; N Sattar; B Cantin; B Lamarche; J-P Després; G R Dagenais; E Barrett-Connor; D Wingard; R Bettencourt; V Gudnason; T Aspelund; G Sigurdsson; B Thorsson; M Trevisan; J Witteman; I Kardys; M Breteler; A Hofman; H Tunstall-Pedoe; R Tavendale; G D O Lowe; Y Ben-Shlomo; B V Howard; Y Zhang; L Best; J Umans; A Onat; T W Meade; I Njolstad; E Mathiesen; M L Lochen; T Wilsgaard; J M Gaziano; M Stampfer; P Ridker; H Ulmer; G Diem; H Concin; F Rodeghiero; A Tosetto; E Brunner; M Shipley; J Buring; S M Cobbe; I Ford; M Robertson; Y He; A M Ibanez; E J M Feskens; D Kromhout; R Collins; E Di Angelantonio; S Kaptoge; S Lewington; L Orfei; L Pennells; P Perry; K Ray; N Sarwar; M Scherman; A Thompson; S Watson; F Wensley; I R White; A M Wood
Journal:  Eur J Epidemiol       Date:  2007-09-18       Impact factor: 8.082

8.  Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.

Authors:  Rebecca K Simmons; Ruth L Coleman; Hermione C Price; Rury R Holman; Kay-Tee Khaw; Nicholas J Wareham; Simon J Griffin
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

  8 in total
  2 in total

1.  Which risk engines are best to assess CVD risk in diabetes?

Authors:  Parinya Chamnan; Rebecca K Simmons; Simon J Griffin
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

2.  Does insulin resistance drive the association between hyperglycemia and cardiovascular risk?

Authors:  Kristine Færch; Bryan Bergman; Leigh Perreault
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.